H.C. Wainwright Sticks to Their Buy Rating for Caladrius Biosciences (CLBS)

By Austin Angelo

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Caladrius Biosciences (CLBSResearch Report), with a price target of $18.50. The company’s shares closed last Thursday at $1.85.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 12.0% and a 44.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

Caladrius Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $18.50.

See today’s analyst top recommended stocks >>

Based on Caladrius Biosciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $4.96 million. In comparison, last year the company had a GAAP net loss of $3.56 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.